Figure 4

Forest plot showing the incidence of the composite renal outcome with SGLT-2 inhibitors compared with placebo in patients with and without chronic kidney disease (CKD). Results are stratified by CKD status. Data are presented as risk ratios (RR) with 95% confidence intervals (95% CI). A lower incidence of the composite renal outcome is identified with SGLT-2 inhibitors compared with placebo in patients with and without CKD (p for interaction 0.30). A random effects model is used. Definition of the composite renal outcome is detailed in Table 1.